Aclaris (NASDAQ:ACRS) has vaulted 19.1% after its postmarket news that its topical wart drug met its goal in a late-stage trial.
The A-101 45% topical solution met its primary and
all secondary efficacy endpoints in a second phase 3 clinical trial,
THWART-1 (WART-301), for treating common warts.
Safety data was comparable to that of the prior THWART-2 trial.
The data will serve as the basis for an NDA filing, the company says.
If approved, the treatment would be the first FDA-approved prescription treatment for common warts, the company says.
https://seekingalpha.com/news/3509514-aclaris-plus-19-percent-positive-results-wart-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.